Marker Therapeutics(US:MRKR) Globenewswireยท2025-05-20 12:00Core Insights - The Phase 1 APOLLO study by Marker Therapeutics shows that lymphodepletion enhances the expansion and persistence of MAR-T cells, potentially improving anti-tumor activity [1][4][5] - The study is focused on MT-601, a MAR-T cell product for patients with lymphoma who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapy [2][9] - The company has reported a significant increase in patient enrollment, surpassing the total from the previous year within the first five months of 2025 [5][7] Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, specializing in T cell-based immunotherapies for hematological malignancies and solid tumors [11] - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating well-tolerated and durable clinical responses [11] Study Details - The APOLLO trial is a multicenter, open-label study evaluating the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma [9] - The primary objective is to assess the optimum dose, safety, and preliminary efficacy of MT-601, with an expected enrollment of approximately 30 participants across nine clinical sites in the U.S. [9] Clinical Data - In the APOLLO study, MT-601 was well tolerated with no dose-limiting toxicities reported, achieving objective responses in 7 out of 9 patients (78%), including 4 complete responses (44.4%) [2][4] - Preliminary data indicates that lymphodepletion supports the expansion and persistence of MT-601 in vivo, with higher levels observed in patients undergoing lymphodepletion compared to those who did not [3][4] Future Outlook - The company anticipates sharing more meaningful clinical data by the end of summer 2025, driven by the increased pace of patient enrollment and positive early clinical results [5][7]